天境生物科技（上海）有限公司 IMab
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
I-Mab to Present Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins's Lymphoma at ASH 2021 2021-11-04 21:00
I-Mab Announces Upcoming Participation at November Conferences 2021-11-03 20:00
I-Mab Strengthens Senior Executive Team with New Chief Financial Officer and Chief Strategy Officer Appointments 2021-11-01 20:00
I-Mab Announces Strategic Partnership with Sinopharm in Preparation for Launch of its Innovative Assets in China 2021-10-26 20:00
I-Mab Expands U.S. Footprint with New R&D Site in San Diego 2021-10-22 20:00
I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China 2021-10-18 20:00
I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (TJ202) in China 2021-10-13 20:00
I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at the 2021 SITC Annual Meeting 2021-10-05 20:00
I-Mab Announces Upcoming Participation at October Conferences 2021-10-01 20:00
I-Mab Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzoparlimab 2021-09-30 20:00
I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors 2021-09-28 20:00
I-Mab Added to FTSE ESG Index Series 2021-09-13 20:00
I-Mab Added to FTSE Russell Global Equity Index Series 2021-09-02 20:00
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2021 2021-08-31 18:00
I-Mab Announces Upcoming Participation at September Conferences 2021-08-30 20:00
I-Mab Announces Establishment of Environmental, Social and Governance Committee 2021-08-19 19:00
I-Mab to Provide Business and Corporate Updates and Report Financial Results for the Six Months Ended June 30, 2021 on August 31, 2021 2021-08-17 20:00
I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease 2021-07-30 20:00
I-Mab Announces Authorization of a Renewed Stock Repurchase Program by the Company up to US$40 Million 2021-07-29 20:00
I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China 2021-07-28 19:15
1 2 3 4 5 6 8